Investigational cancer treatments coverage report /

To comply with 20 ILCS 1405/56.3, the Illinois Dept. of Insurance was required to conduct a three year report (2000-2002), which included an analysis of the effect of the coverage requirements on the cost of insurance and health care; the results of the treatments to patients; the mortality rate among cancer patients; any improvements in care of patients; and any imporvements in the quality of life of patients.

Signing treatments for interchange lane drops /

Final report.

Imported fire ant : quarantine treatments for nursery stock and other regulated articles.

"Issued 1999"--P. [2] of cover.

Nitrogen and carbon changes in Great Plains soils as influenced by cropping and soil treatments /

Chiefly tables.

Influences of vegetation and watershed treatments on run-off, silting, and stream flow : a progress report of research /

Caption title.

Reduction in the plant uptake of Sr-90 by soil management treatments

Bibliography: p. 29-30.

Timing and duration of release treatments affect vegetation development in a young California white fir plantation /

"March 2001"--P. [2] of cover.

Solar treatments for reducing survival of mountain pine beetle in infested ponderosa and lodgepole pine logs /

"September 2001."

Value Assessment of Orphan Drugs and Treatments for Rare Diseases

Thesis (Master's)--University of Washington, 2016-06

Hypertension and diabetes treatments and risk of adverse outcomes among breast cancer patients

Thesis (Ph.D.)--University of Washington, 2016-06

Stem and Branch Diameter Response in Pruned Douglas-fir Plantations (Pseudotsuga menziesii var. menziesii): Implications for Volume and Clear Wood Production in the U.S. Pacific Northwest

Thesis (Master's)--University of Washington, 2016-06

Effects of 6-benzylaminopurine treatments on the longevity of harvested Grevillea 'Sylvia' inflorescences

Exogenous treatments with cytokinins, such as 6-benzylaminopurine (BA), can delay senescence of some plant tissues. Grevillea 'Sylvia' inflorescences have a short vase life. BA supplied in vase solutions at up to 0.1 mM did not delay senescence of G. 'Sylvia' in florescences. However, BA applied by dipping at concentrations up to 10 mM extended their vase life (longevity). Senescence parameters of relative fresh weight, flower abscission, flower opening, flower discolouration and flower wilting were all suppressed by BA dips. Dip treatment with BA (1 mM) was effective on G. 'Sylvia' in florescences at three different maturity stages.

Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments

After initial infection, human cytomegalovirus remains in a persistent state with the host. Immunity against the virus controls replication, although intermitent viral shedding can still take place in the seropositive immunocompetent person. Replication of cytomegalovirus in the absence of an effective immune response is central to the pathogenesis of disease. Therefore, complications are primarily seen in individuals whose immune system is immature, or is suppressed by drug treatment or coinfection with other pathogens. Although our increasing knowledge of the host-virus relationship has lead to the development of new pharmacological strategies for cytomegalovirus-associated infections, these strategies all have limitations-eg, drug toxicities, development of resistance, poor oral bioavailability, and low potency. Immune-based therapies to complement pharmacological strategies for the successful treatment of virus-associated complications should be prospectively investigated.

Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: a randomized controlled trial

To investigate the effects of different management strategies for non-localized prostate cancer on men's quality of life and cognitive functioning. Men with prostate cancer were randomly assigned to one of four treatment arms: leuprorelin, goserelin, cyproterone acetate (CPA), or close clinical monitoring. In a repeated-measures design, men were assessed before treatment (baseline) and after 6 and 12 months of treatment. A community comparison group of men of the same age with no prostate cancer participated for the same length of time. The men were recruited from public and private urology departments from university teaching hospitals. All those with prostate cancer who were eligible for hormonal therapy had no symptoms requiring immediate therapy. In all, 82 patients were randomized and 62 completed the 1-year study, and of the 20 community participants, 15 completed the study. The main outcome measures were obtained from questionnaires on emotional distress, existential satisfaction, physical function and symptoms, social and role function, subjective cognitive function, and sexual function, combined with standard neuropsychological tests of memory, attention, and executive functions. Sexual dysfunction increased for patients on androgen-suppressing therapies, and emotional distress increased in those assigned to CPA or close clinical monitoring. Compared with before treatment there was evidence of an adverse effect of leuprorelin, goserelin, and CPA on cognitive function. In deciding the timing of androgen suppression therapy for prostate cancer, consideration should be given to potential adverse effects on quality of life and cognitive function.